Nivolumab for advanced non-small cell lung cancer: an evaluation of a phase III study

被引：5

作者：

Ulmeanu, Ruxandra ^{[1
,2
]}

Antohe, Ileana ^{[3
]}

Anisie, Ecaterina ^{[4
]}

Antoniu, Sabina ^{[3
]}

机构：

[1] Marius Nasta Inst, Bucharest, Romania

[2] Univ Med Oradea, Fac Med, Bucharest, Romania

[3] Univ Med & Pharm Gr T Popa, Dept Interdisciplinar & Prevent Med, Iasi, Romania

[4] Sf Spiridon Univ Hosp, Immunol Lab, Iasi, Romania

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2016年 / 16卷 / 02期

关键词：

monoclonal antibody; lung cancer; PD-1; Nivolumab; SAFETY; ANTIBODY;

D O I：

10.1586/14737140.2016.1127760

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Lung cancer still remains associated with a high mortality rate and more efficacious therapies are needed in order to improve the disease outcome. Nivolumab is a monoclonal antibody which blocks the programmed death-1 receptor which is currently evaluated in phase III clinical trials in advanced lung cancer. Here, we evaluate the results of a phase III study in which nivolumab efficacy and safety were compared to those of docetaxel. Nivolumab was able to improve survival and progression-free survival and exhibited a very good safety profile. Further clinical data are needed in order to better position this therapy among the existing methods. The promising results support the use of this therapy as a stand-alone approach.

引用

页码：165 / 167

页数：3

共 12 条

[1] Epidemiology of Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [J].

Alberg, Anthony J. ;

Brock, Malcolm V. ;

Ford, Jean G. ;

Samet, Jonathan M. ;

Spivack, Simon D. .

CHEST, 2013, 143 (05) :E1-E29

[2]

[Anonymous], 2015, FDA EXP APPR US OPD

[3]

[Anonymous], ASCO M S

[4] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[5] Nivolumab: targeting PD-1 to bolster antitumor immunity [J].

Brahmer, Julie R. ;

Hammers, Hans ;

Lipson, Evan J. .

FUTURE ONCOLOGY, 2015, 11 (09) :1307-1326

[6] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].

Brahmer, Julie R. ;

Tykodi, Scott S. ;

Chow, Laura Q. M. ;

Hwu, Wen-Jen ;

Topalian, Suzanne L. ;

Hwu, Patrick ;

Drake, Charles G. ;

Camacho, Luis H. ;

Kauh, John ;

Odunsi, Kunle ;

Pitot, Henry C. ;

Hamid, Omid ;

Bhatia, Shailender ;

Martins, Renato ;

Eaton, Keith ;

Chen, Shuming ;

Salay, Theresa M. ;

Alaparthy, Suresh ;

Grosso, Joseph F. ;

Korman, Alan J. ;

Parker, Susan M. ;

Agrawal, Shruti ;

Goldberg, Stacie M. ;

Pardoll, Drew M. ;

Gupta, Ashok ;

Wigginton, Jon M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465

[7] Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer [J].

Gettinger, Scott N. ;

Horn, Leora ;

Gandhi, Leena ;

Spigel, David R. ;

Antonia, Scott J. ;

Rizvi, Naiyer A. ;

Powderly, John D. ;

Heist, Rebecca S. ;

Carvajal, Richard D. ;

Jackman, David M. ;

Sequist, Lecia V. ;

Smith, David C. ;

Leming, Philip ;

Carbone, David P. ;

Pinder-Schenck, Mary C. ;

Topalian, Suzanne L. ;

Hodi, F. Stephen ;

Sosman, Jeffrey A. ;

Sznol, Mario ;

McDermott, David F. ;

Pardoll, Drew M. ;

Sankar, Vindira ;

Ahlers, Christoph M. ;

Salvati, Mark ;

Wigginton, Jon M. ;

Hellmann, Matthew D. ;

Kollia, Georgia D. ;

Gupta, Ashok K. ;

Brahmer, Julie R. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18) :2004-U32

[8] The blockade of immune checkpoints in cancer immunotherapy [J].

Pardoll, Drew M. .

NATURE REVIEWS CANCER, 2012, 12 (04) :252-264

[9] Immune Checkpoint Blockade in Cancer Therapy [J].

Postow, Michael A. ;

Callahan, Margaret K. ;

Wolchok, Jedd D. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (17) :1974-U161

[10] Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial [J].

Rizvi, Naiyer A. ;

Mazieres, Julien ;

Planchard, David ;

Stinchcombe, Thomas E. ;

Dy, Grace K. ;

Antonia, Scott J. ;

Horn, Leora ;

Lena, Herve ;

Minenza, Elisa ;

Mennecier, Bertrand ;

Otterson, Gregory A. ;

Campos, Luis T. ;

Gandara, David R. ;

Levy, Benjamin P. ;

Nair, Suresh G. ;

Zalcman, Gerard ;

Wolf, Juergen ;

Souquet, Pierre-Jean ;

Baldini, Editta ;

Cappuzzo, Federico ;

Chouaid, Christos ;

Dowlati, Afshin ;

Sanborn, Rachel ;

Lopez-Chavez, Ariel ;

Grohe, Christian ;

Huber, Rudolf M. ;

Harbison, Christopher T. ;

Baudelet, Christine ;

Lestini, Brian J. ;

Ramalingam, Suresh S. .

LANCET ONCOLOGY, 2015, 16 (03) :257-265

← 1 2 →